The therapeutic landscape for diffuse large B-cell lymphoma (DLBL) has evolved significantly in recent years, with new innovative products enriching the therapeutic arsenal, offering promising options, and the most recent guidelines providing a valuable framework for this new treatment algorithm.
Dr Vibeke Vergote
Vibeke Vergote, MD is a hematologist at the University Hospital Leuven (Belgium) since 2016. She completed her medical degree at the KU Leuven and trained as a hematologist at the University Hospitals Leuven.
Dr Vergote’s special interest is the treatment of patients with aggressive lymphoma and mantle cell lymphoma, autologous stem cell transplantation and apheresis. She is involved in several clinical lymphoma studies.
Currently, she is doing her PhD on novel imaging techniques in aggressive lymphoma. She is member of the lymphoma subcommittee of the BHS and the HOVON lymphoma working party.
Following the latest DLBCL guidelines published in June 2024 and key takeaways from the DLBCL webinar held on 24 September 2024, Dr. Vergote from UZ Leuven offers a critical evaluation of the evolving treatment landscape.
In short interviews, she elaborate on the integration of novel therapies, particularly polatuzumab and glofitamab into the updated treatment guidelines.
Polatuzumab (Polivy ®▼) in 1st line DLBCL 1,*
*M-BE-00002927
Glofitamab (Columvi ®▼ ) in 3rd line DLBCL 2*
*M-BE-00002927
Discover additional perspectives on Glofitamab (Columvi®▼) from an international healthcare professional 2,**
Professor Chris Fox
Professor Chris Fox, hematologist at Nottingham University Hospitals NHS Trust, specializes in lymphoma and stem cell research. With a robust research background, he is dedicated to advancing treatments for blood cancers and improving outcomes through stem cell transplantation. His work effectively bridges clinical care and research, contributing to the development of better therapies for haematological diseases.
References :
1. Polivy SmPC - 24/05/2022 : https://www.e-compendium.be/fr/notices/scientifique/8330/19743
2. Columvi SmPC- 16/09/2024 : https://www.e-compendium.be/fr/notices/scientifique/8330/19743
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Polivy SmPC - 24/05/2022 : https://www.e-compendium.be/fr/notices/scientifique/8330/19743
Columvi SmPC- 16/09/2024 : https://www.e-compendium.be/fr/notices/scientifique/8330/19743